Sleep apnea is the one obesity-related condition where the trial evidence and the price question collide most directly. The result is large and unusually clean. The dose it was produced at is near the top of the ladder, and the ladder is the thing this market is worst at publishing — and tirzepatide is already the dearer of the two molecules before any of that, as the tirzepatide premium sets out.
What the trials found
SURMOUNT-OSA ran as two parallel phase 3 trials in adults with moderate-to-severe obstructive sleep apnea and obesity [1]. Trial 1 enrolled people not receiving positive airway pressure therapy; trial 2 enrolled people who were. Both randomized 1:1 to the maximum tolerated dose of tirzepatide — 10 mg or 15 mg — or placebo, for 52 weeks.
Participants arrived severely affected. Mean BMI was 39.1 in the first trial and 38.7 in the second, and the index itself averaged just over 50 events an hour in both.
By week 52 the drug arms had improved by 25.3 and 29.3 events an hour. What makes those numbers interpretable is the placebo arms, which moved only 5.3 and 5.5 — everyone in both trials was also receiving lifestyle intervention, so the placebo change is what that intervention bought on its own. Subtracting leaves the drug’s own contribution: 20.0 events an hour in the first trial (95% CI 25.8 to 14.2) and 23.8 in the second (95% CI 29.6 to 17.9), each at p<0.001. Every prespecified key secondary endpoint moved with it.
An index above 30 is severe by convention. These participants started at around 50 and finished, on average, in the twenties. That is a category change rather than an improvement at the margin, which is rare enough in this literature to be worth saying plainly.
The dose is the price
Every number above was produced at 10 mg or 15 mg, held for a year. That is not where a buyer starts. It is where a buyer arrives, if the escalation goes as planned, several months in — and what the bill does on the way there is the question this roster mostly does not answer.
Across 456 sellers, 278 — 61% of them — publish nothing about what happens to the price as the dose rises. The rest split between stating a flat rate and stating that the figure climbs. Only the first of those is a promise a reader can hold anyone to, and we count the whole distribution in nobody says what happens at a higher dose.
Before buying for this reason
A sleep study is the thing that establishes there is a problem, how bad it is, and whether anything changed. It is also the one part of this that a telehealth intake form does not do. If the reason for interest is apnea rather than weight, the order of operations is diagnosis first — and the seller comparison second, which is what what a GLP-1 actually costs and where choice runs out are for.
It is also worth knowing that the dose these trials used sits at the far end of an escalation most people do not complete: the discontinuation figures in two-thirds stop within a year describe the same journey from the other side.